RESEARCH MONOGRAPH · KDC-MN-359

Bimagrumab

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

71/100

ActRII-blocking antibody with body composition effects too striking to ignore, mostly killed by trial design choices

Bimagrumab is the drug where the body composition data made everyone do a double-take. Anti-activin receptor type II monoclonal antibody (binds both IIA and IIB), originally developed by Novartis for inclusion body myositis and sarcopenia, but the most attention came from the type 2 diabetes and obesity trials.

The mechanism is clean. ActRII activation drives muscle catabolism and reduces lean mass through the myostatin and activin signaling network. Block both receptor subtypes with a high-affinity antibody and you simultaneously increase muscle protein synthesis and reduce muscle protein breakdown. The result in trials was striking: roughly 20 percent increase in lean mass and 7 to 8 percent decrease in fat mass after several months of dosing in T2D patients (Heymsfield and Hosgood paper, JAMA Network Open 2021). Honestly those numbers are hard to produce with anything else short of GLP-1 plus resistance training, and the body composition shift goes the opposite direction (more muscle, less fat) compared to most weight loss interventions.

Then the inclusion body myositis trial (RESILIENT) didn't hit its primary endpoint, which is where the development trajectory complicated. The disease is brutal, the trial design may not have been right, and the muscle mass effects didn't translate to the functional improvement endpoints the regulators needed. Novartis sold the asset to Versanis, which is now developing it for obesity in combination with GLP-1 receptor agonists. That combination is honestly one of the more exciting near-term obesity pharmacology stories.

What's intriguing is the dual-receptor coverage. By blocking IIA and IIB simultaneously, bimagrumab captures more of the pathway than myostatin-specific approaches, which probably explains the larger effect size compared to anti-myostatin antibodies. The trade-off is the broader ligand network (activin, BMP) that gets affected.

Sourcing as a research antibody is limited. Bimagrumab is proprietary, and research-grade ActRII antibodies suitable as surrogates do exist but the affinity and effector function profiles vary.

What we dont love is the muscle weakness reports in some IBM trial participants. Honestly the safety profile in healthy populations and in T2D looks acceptable, but in disease states the calculus has been more complicated. The combination with GLP-1 RAs is where the next chapter happens and we're watching it.

Evidence: 75
Mechanism: 88
Reliability: 75
Safety: 65
Sourcing: 50
Value: 55
Signal: 82
Staying power: 78

Plain-language summary Intrigue 64 / 100

Bimagrumab is a humanized antibody against the activin receptor type II (the receptor that myostatin and related ligands bind) developed by Novartis and MorphoSys. By blocking the receptor at the cell surface, it prevents engagement by myostatin, activin A, and GDF-11 in one shot. It has been investigated for sporadic inclusion body myositis, sarcopenia, and (more recently) obesity-related muscle preservation, where it has produced meaningful fat loss alongside muscle gain in early trials. Most trials have not met primary endpoints in muscle disease populations, but the obesity application has revived clinical interest. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Anti-activin receptor type II monoclonal antibody

A humanized monoclonal antibody against activin receptor type II; investigated for sarcopenia, sIBM, and obesity-related muscle preservation.

Abstract

Bimagrumab (BYM338; humanized IgG1 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized monoclonal antibody against activin receptor type II (ActRII), developed at MorphoSys and Novartis. The compound binds ActRIIA and ActRIIB receptors on the cell surface, blocking access by myostatin, activin A, and GDF-11; the receptor-level blockade is mechanistically distinct from ligand traps (ACE-031) and from selective myostatin antibodies (stamulumab). Phase 2 trials in sporadic inclusion body myositis (RESILIENT) and sarcopenia demonstrated muscle mass increases. The compound generated substantial interest in 2020 after a phase 2 trial in obesity with type 2 diabetes (BIM-T2D) showed approximately 21 percent reduction in fat mass with concurrent muscle preservation, an unusual profile that has subsequently driven obesity-related development. Used as a research probe for receptor-level myostatin pathway inhibition.

Mechanism of action

Monoclonal antibody against activin receptor type II (ActRIIA/B); blocks receptor at cell surface from binding myostatin, activin A, GDF-11.

Reported research dose ranges

Trial doses 3 to 30 mg/kg intravenous every 4 weeks; subcutaneous 700 to 2100 mg every 4 weeks.

References

Heymsfield SB, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity. JAMA Netw Open 2021.
Amato AA, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology 2014.
Rooks D, et al. Bimagrumab vs optimized standard of care for treatment of sarcopenia. JAMA Netw Open 2017.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-359

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Bimagrumab

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs